Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Publication/Presentation Date
3-1-2006
Abstract
Her-2 is a validated therapeutic target in breast cancer. The two critical questions that remain regarding Her-2 targeting concern 1) the relevance of Her-2 inhibition in other malignancies and 2) the ability of novel agents to achieve greater Her-2 inhibition than trastuzumab. The contribution of cell signaling effects and immunologic mechanisms to the effect of trastuzumab in vivo remains poorly understood. Thus, the preclinical data that support the greater efficacy of novel Her-2 antibodies or small molecule tyrosine kinase inhibitors remain to be validated in clinical trials. In this review, we discuss the evidence from recent trastuzumab clinical trials as a point of departure for consideration of novel Her-2 targeted therapies. Preliminary results from early clinical trials suggest that Her-2 tyrosine kinase inhibitors may extend the population for which this strategy offers therapeutic effect.
Volume
8
Issue
2
First Page
90
Last Page
95
ISSN
1523-3790
Published In/Presented At
Flaherty, K. T., & Brose, M. S. (2006). Her-2 targeted therapy: beyond breast cancer and trastuzumab. Current oncology reports, 8(2), 90–95. https://doi.org/10.1007/s11912-006-0042-4
Disciplines
Medicine and Health Sciences
PubMedID
16507217
Department(s)
Hematology-Medical Oncology Division
Document Type
Article